Evidence map›Paper›PMID 37515650›Full record

ArticleWorld journal of urology2023

Holmium laser with MOSES technology (MoLEP) vs Thulium fiber laser enucleation of the prostate (ThuFLEP) in a real-world setting. Mid-term outcomes from a multicenter propensity score analysis.

Daniele Castellani, Mirko Di Rosa, Fernando Gómez Sancha, Moisés Rodríguez Socarrás, Abhay Mahajan, Mohammed Taif Bendigeri, Mark Taratkin, Dmitry Enikeev, Marco Dellabella, Nariman Gadzhiev and 3 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in World journal of urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Thulium fiber laser versus holmium MOSESProstate cancer and prostatic diseases · 2026
    Trial
  3. Best of 2025 in prostate cancer and prostatic diseases.Prostate cancer and prostatic diseases · 2026
    Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 7 countries.

Daniele CastellaniUrology Unit, IRCCS INRCA, Ancona, Italy.ORCID http://orcid.org/0000-0001-7354-9190
Mirko Di RosaUnit of Geriatric Pharmacoepidemiology and Biostatistics, Center for Biostatistic and Applied Geriatric Clinical Epidemiology, IRCCS INRCA, Via Santa Margherita 5, 60124, Ancona, Italy. m.dirosa@inrca.it.
Fernando Gómez SanchaDepartment of Urology and Robotic Surgery, ICUA-Clínica CEMTRO, Madrid, Spain.
Moisés Rodríguez SocarrásDepartment of Urology and Robotic Surgery, ICUA-Clínica CEMTRO, Madrid, Spain.
Abhay MahajanDepartment of Urology, Mahatma Gandhi Mission's Medical College and Hospital, Aurangabad, India.
Mohammed Taif BendigeriDepartment of Urology, Asian Institute of Nephrology and Urology, Hyderabad, India.
Mark TaratkinInstitute for Urology and Reproductive Health, Sechenov University, Moscow, Russian Federation.
Dmitry EnikeevInstitute for Urology and Reproductive Health, Sechenov University, Moscow, Russian Federation.
Marco DellabellaUrology Unit, IRCCS INRCA, Ancona, Italy.
Nariman GadzhievDepartment of Urology, Saint-Petersburg State University Hospital, Saint-Petersburg, Russia.
Bhaskar Kumar SomaniDepartment of Urology, University Hospitals Southampton NHS Trust, Southampton, UK.
Thomas R W HerrmannDepartment of Urology, Kantonspital Frauenfeld, Spital Thurgau AG, Frauenfeld, Switzerland.
Vineet GauharDepartment of Urology, Ng Teng Fong General Hospital, Singapore, Singapore.
Clínica Rementería · ESSechenov University · RUAsian Institute of Gastroenterology · INIstituti di Ricovero e Cura a Carattere Scientifico · ITIstituto Nazionale di Riposo e Cura per Anziani · ITMahatma Gandhi Mission Medical College and Hospital · INMarche Polytechnic University · ITNg Teng Fong General Hospital · SGSpital Thurgau (Switzerland) · CHSt Petersburg University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo compare Holmium laser with MOSES technology (MoLEP) and Thulium fiber laser enucleation of the prostate (ThuFLEP) in terms of surgical and functional outcomes.

methodsWe performed a retrospective analysis of all patients who underwent either procedure in five centers (January 2020-January 2022). EXCLUSION CRITERIA: previous urethral/prostatic surgery, radiotherapy, concomitant surgery. Propensity score matching (PSM) analysis was performed to adjust for the bias inherent to the different characteristics at baseline. Differences between procedures were estimated using Firth Penalized Likelihood regression for International prostate symptom score (IPSS), quality of life (QL), maximum flow rate (Qmax).

resultsPSM retrieved 118 patients in each group. Baseline characteristics were similar except for PSA and number of men on indwelling catheter (higher in MoLEP group). Median surgical time was significantly longer in the MoLEP group despite the enucleation and morcellation times being similar. Median catheter dwelling time and postoperative length of stay were similar. Most of the early complications were Clavien ≤ 2 grade. There were only two Clavien grade 3 complications (one for each group), one grade 4 in MoLEP group. Rate and type of early and persistent incontinence (> 3 months) were similar. At 12-month, proportion of patients reaching a decrease (Δ) of IPSS ≥ 18 from baseline was significantly larger in MoLEP group, with no significant difference in ΔQmax > 12 ml/sec and ΔQL ≥ -3.

conclusionMoLEP and ThuFLEP were safe and efficacious procedures with similar short-term operative and functional outcomes. At 1-year, MoLEP patients had a sustained reduction of IPPS score.

Indexed as

Lasers, Solid-StateLaser TherapyProstatic HyperplasiaHumansMalePropensity ScoreProstateQuality of LifeRetrospective StudiesThuliumTreatment OutcomeThuliumBenign prostatic hyperplasiaEndoscopic enucleation of the prostateLaser therapyMoLEPThuFLEP

Identifiers

PMID37515650
OpenAlexW4385380561

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.